Letrozole CAS 112809-51-5 API Factory Aromatase Inhibitor II High Quality

Short Description:

Chemical Name: Letrozole

CAS: 112809-51-5

Appearance: White to Off-White Crystalline Powder

Assay: 98.0%~102.0%

For advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Supply with High Purity and Stable Quality
Chemical Name: Letrozole
CAS: 112809-51-5 
Aromatase Inhibitor II
API High Quality, Commercial Production

Chemical Properties:

Chemical Name Letrozole
Synonyms CGS-20267; Femara
CAS Number 112809-51-5
CAT Number RF-API86
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C17H11N5
Molecular Weight 285.3
Melting Point 181.0 to 183.0℃
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Crystalline Powder
Solubility  Freely Soluble in Dichloromethane, Slightly Soluble in Ethanol and Practically Insoluble in Water
Identification IR  Spectrum of the sample corresponds to that of reference standard
Identification HPLC The retention time of the test sample corresponds to that of the reference standard
Water Content (by K.F) ≤0.30%
Residue on Ignition ≤0.10% 
Related Substances
Related Substances A ≤0.30%
Related Substances B ≤0.20%
Any Unspecified Impurity ≤0.10%
Total Unspecified  Impurities ≤0.30%
Total Impurities ≤0.50%
Residual Solvents
Ethyl Acetate ≤0.50%
Methanol ≤0.30%
Ethanol ≤0.50%
DMF ≤0.088%
Heavy Metals ≤10ppm
Assay  98.0%~102.0% (on the anhydrous basis )
Shelf Life 24 Months
Test Standard Enterprise Standard
Usage API, Aromatase Inhibitor II

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

Letrozole (CAS 112809-51-5) is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment.

  • Write your message here and send it to us